肺大细胞神经内分泌癌临床分子诊断和治疗研究进展

doi:10.3760/cma.j.cn371439-20231130-00077

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (7): 468-473.doi: 10.3760/cma.j.cn371439-20231130-00077

肺大细胞神经内分泌癌临床分子诊断和治疗研究进展

韩艺¹, 张同梅²^,³, 齐菲²^,³, 张泳⁴()

¹陕西中医药大学第一临床医学院，咸阳 712046
²首都医科大学附属北京胸科医院综合科，北京 101149
³首都医科大学基础临床联合实验室，北京 101149
⁴陕西中医药大学附属医院胸心外科，咸阳 712000

收稿日期:2023-11-30 修回日期:2024-03-27 出版日期:2024-07-08 发布日期:2024-08-14
通讯作者: 张泳，Email： zhangyong126126@126.com
基金资助:
北京市属医学科研院所公益发展改革试点项目(JYY2023-14);北京市属医学科研院所公益发展改革试点项目(JYY2023-15)

Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma

Han Yi¹, Zhang Tongmei²^,³, Qi Fei²^,³, Zhang Yong⁴()

¹First School of Clinical Medicine of Shaanxi University of Chinese Medicine， Xianyang 712046， China
²Department of General， Beijing Chest Hospital， Capital Medical University， Beijing 101149， China
³Laboratory for Clinical Medicine， Capital Medical University， Beijing 101149， China
⁴Department of Cardiothoracic Surgery， Affiliated Hospital of Shaanxi University of Chinese Medicine， Xianyang 712000， China

Received:2023-11-30 Revised:2024-03-27 Online:2024-07-08 Published:2024-08-14
Contact: Zhang Yong， Email： zhangyong126126@126.com
Supported by:
Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes(JYY2023-14);Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes(JYY2023-15)

摘要/Abstract

摘要：

肺大细胞神经内分泌癌（LCNEC）是一类少见的恶性神经内分泌肿瘤，总体预后不佳，晚期患者中位总生存期仅1年左右。随着分子诊断、靶向治疗和免疫治疗的应用，非小细胞肺癌患者预后显著改善，然而LCNEC诊疗的进展相对缓慢，目前尚无统一标准的诊断、治疗方案。LCNEC临床分子诊断和治疗研究具有重要意义，探讨LCNEC诊断、治疗相关研究进展，可为改善LCNEC现存临床诊断、治疗困境提供参考。

关键词: 肺肿瘤, 癌, 神经内分泌, 病理学, 分子, 肿瘤治疗方案, 免疫检查点抑制剂

Abstract:

Pulmonary large cell neuroendocrine carcinoma （LCNEC） is a rare type of malignant neuroendocrine tumor with poor prognosis， with the median overall survival being around one year in advanced diseases. The prognosis of patients with non-small cell lung cancer has been greatly improved with the application of molecular detecting techniques， targeted therapy and immunotherapy. However， little progress has been made in the diagnosis and treatment of LCNEC with no unified standard of diagnosis and treatment protocol. The clinical molecular diagnosis and treatment of LCNEC is of great significance. Exploring the research progress related to the diagnosis and treatment of LCNEC can provide reference for improving the existing clinical diagnosis and treatment difficulties of LCNEC.

Key words: Lung neoplasms, Carcinoma, neuroendocrine, Pathology, molecular, Antineoplastic protocols, Immune checkpoint inhibitors

韩艺, 张同梅, 齐菲, 张泳. 肺大细胞神经内分泌癌临床分子诊断和治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 468-473.

Han Yi, Zhang Tongmei, Qi Fei, Zhang Yong. Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma[J]. Journal of International Oncology, 2024, 51(7): 468-473.

参考文献 44

[1]	Minami Y. Ⅲ. The notable topics of the 5th Edition of WHO Classification for the Thoracic Tumours(2021)[J]. Gan To Kagaku Ryoho, 2022, 49(8): 847-852. pmid: 36046969
[2]	Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges[J]. Mod Pathol, 2022, 35(Suppl 1): 36-50. DOI: 10.1038/s41379-021-00943-2.
[3]	Metovic J, Barella M, Bianchi F, et al. Morphologic and molecular classification of lung neuroendocrine neoplasms[J]. Virchows Arch, 2021, 478(1): 5-19. DOI: 10.1007/s00428-020-03015-z.
[4]	Shah S, Gosain R, Groman A, et al. Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States[J]. Cancers (Basel), 2021, 13(8): 1753. DOI:10.3390/cancers13081753.
[5]	孟宇, 练延帮, 许跃, 等. 支气管肺大细胞神经内分泌癌的临床和分子病理特点[J]. 中华医学杂志, 2022, 102(14): 1020-1027. DOI: 10.3760/cma.j.cn112137-20210814-01816.
[6]	Krpina K, Vranić S, Tomić K, et al. Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives[J]. Biomedicines, 2023, 11(7): 1982. DOI:10.3390/biomedicines11071982.
[7]	Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets[J]. Clin Cancer Res, 2016, 22(14): 3618-3629. DOI: 10.1158/1078-0432.CCR-15-2946. pmid: 26960398
[8]	George J, Walter V, Peifer M, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors[J]. Nat Commun, 2018, 9(1): 1048. DOI:10.1038/s41467-018-03099-x. pmid: 29535388
[9]	Miyoshi T, Umemura S, Matsumura Y, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung[J]. Clin Cancer Res, 2017, 23(3): 757-765. DOI: 10.1158/1078-0432.CCR-16-0355. pmid: 27507618
[10]	Cao L, Li ZW, Wang M, et al. Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study[J]. PeerJ, 2019, 7: e6539. DOI: 10.7717/peerj.6539.
[11]	Peng KW, Cao HJ, You YF, et al. Optimal surgery type and adjuvant therapy for T₁N₀M₀ lung large cell neuroendocrine carcinoma[J]. Front Oncol, 2021, 11: 591823. DOI: 10.3389/fonc.2021.591823.
[12]	Lowczak A, Kolasinska-Cwikla A, Ćwikła JB, et al. Outcomes of patients with clinical stage Ⅰ-ⅢA large-cell neuroendocrine lung cancer treated with resection[J]. J Clin Med, 2020, 9(5): 1370. DOI:10.3390/jcm9051370.
[13]	Raman V, Jawitz OK, Yang CJ, et al. Outcomes for surgery in large cell lung neuroendocrine cancer[J]. J Thorac Oncol, 2019, 14(12): 2143-2151. DOI: 10.1016/j.jtho.2019.09.005. pmid: 31557535
[14]	Chen H, Ishihara M, Horita N, et al. Effect of adjuvant and palliative chemotherapy in large cell neuroendocrine carcinoma of the lung: a systematic review and meta-analysis[J]. Cancers (Basel), 2021, 13(23): 5948. DOI:10.3390/cancers13235948.
[15]	Gu JJ, Gong DH, Wang YX, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung[J]. Cancer Med, 2019, 8(6): 2979-2993. DOI: 10.1002/cam4.2188.
[16]	Wakeam E, Adibfar A, Stokes S, et al. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma[J]. J Thorac Cardiovasc Surg, 2020, 159(5): 2043-2054.e9. DOI: 10.1016/j.jtcvs.2019.09.077. pmid: 31759623
[17]	Andreetti C, Ibrahim M, Gagliardi A, et al. Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neu-roendocrine carcinoma[J]. Thorac Cancer, 2022, 13(7): 900-912. DOI: 10.1111/1759-7714.14287. pmid: 35170859
[18]	Raman V, Jawitz OK, Yang CJ, et al. Adjuvant therapy for patients with early large cell lung neuroendocrine cancer: a national analysis[J]. Ann Thorac Surg, 2019, 108(2): 377-383. DOI: 10.1016/j.athoracsur.2019.03.053.
[19]	Haruki T, Matsui S, Oshima Y, et al. Prognostic impact of surgical treatment for high-grade neuroendocrine carcinoma of the lung: a multi-institutional retrospective study[J]. J Thorac Dis, 2022, 14(4): 1070-1078. DOI: 10.21037/jtd-21-1938. pmid: 35572862
[20]	Kenmotsu H, Niho S, Tsuboi M, et al. Randomized phase Ⅲ study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205/1206[J]. J Clin Oncol, 2020, 38(36): 4292-4301. DOI: 10.1200/JCO.20.01806.
[21]	Gang J, Xue L, Xiang S. The role of postoperative radiotherapy (PORT) in pulmonary large cell neuroendocrine carcinoma (PLCNEC)[J]. Cancer Radiothérapie, 2020, 24(3): 215-221. DOI: 10.1016/j.canrad.2020.02.004.
[22]	Jiang YZ, Lei C, Zhang XF, et al. Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma[J]. J Cancer, 2019, 10(25): 6422-6430. DOI: 10.7150/jca.32446. pmid: 31772675
[23]	Limonnik V, Abel S, Finley GG, et al. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: a national cancer database analysis[J]. Lung Cancer, 2020, 150: 107-113. DOI: 10.1016/j.lungcan.2020.10.001. pmid: 33126090
[24]	Le Treut J, Sault MC, Lena H, et al. Multicentre phase Ⅱ study of cisplatin-etoposide chemotherapy for advanced large-cell neu-roendocrine lung carcinoma: the GFPC 0302 study[J]. Ann Oncol, 2013, 24(6): 1548-1552. DOI: 10.1093/annonc/mdt009. pmid: 23406729
[25]	Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase Ⅱ study[J]. J Thorac Oncol, 2013, 8(7): 980-984. DOI: 10.1097/JTO.0b013e31828f6989.
[26]	Derks JL, van Suylen RJ, Thunnissen E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?[J]. Eur Respir J, 2017, 49(6): 1601838. DOI:10.1183/13993003.01838-2016.
[27]	Ogikubo M, Isaka T, Ishikawa Y, et al. Postoperative relapse of combined large-cell neuroendocrine carcinoma of the lung with a remarkable transient response to amrubicin monotherapy in an elderly patient—a case report[J]. Gan to kagaku ryoho, 2021, 48(5): 681-683. pmid: 34006713
[28]	Ørting AM, Clausen MM, Soldath P, et al. Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide[J]. Acta Oncol, 2023, 62(12): 1952-1955. DOI: 10.1080/0284186X.2023.2258444.
[29]	Dudnik E, Kareff S, Moskovitz M, et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung[J]. J Immunother Cancer, 2021, 9(2): e001999. DOI: 10.1136/jitc-2020-001999.
[30]	Meng L, Cao B, Ji R, et al. Enhanced efficacy of chemotherapy by addition of immune checkpoint inhibitors in stage Ⅳ large cell neuroendocrine carcinoma of the lung: a real-world analysis[J]. J Cancer, 2023, 14(17): 3169-3175. DOI: 10.7150/jca.87052.
[31]	Zhang X, Sun YB, Miao Y, et al. Immune checkpoint inhibitor therapy achieved complete response for drug-sensitive EGFR/ALK mutation-negative metastatic pulmonary large-cell neuroendocrine carcinoma with high tumor mutation burden: a case report[J]. Onco Targets Ther, 2020, 13: 8245-8250. DOI: 10.2147/OTT.S259893.
[32]	Takimoto Sato M, Ikezawa Y, Sato M, et al. Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: a case report[J]. Mol Clin Oncol, 2020, 13(1): 43-47. DOI: 10.3892/mco.2020.2045. pmid: 32499913
[33]	Chen F, Hua HB, Huang HQ. Neoadjuvant chemotherapy combined with immunotherapy for pulmonary large-cell neuroendocrine carcinoma: a case report[J]. Ann Palliat Med, 2021, 10(7): 8479-8483. DOI: 10.21037/apm-20-2536. pmid: 34118833
[34]	Arpin D, Charpentier MC, Bernardi M, et al. PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study[J]. Ther Adv Med Oncol, 2020, 12: 1758835920937972. DOI: 10.1177/1758835920937972.
[35]	Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer[J]. Clin Cancer Res, 2020, 26(21): 5701-5708. DOI: 10.1158/1078-0432.CCR-20-1825.
[36]	李杨仪, 龚龑, 谢丛华. SAMHD1抑制肺腺癌细胞中PD-L1表达的研究[J]. 国际肿瘤学杂志, 2022, 49(11): 658-664. DOI: 10.3760/cma.j.cn371439-20220427-00130.
[37]	Peng WY, Cao LM, Chen LK, et al. Comprehensive characterization of the genomic landscape in Chinese pulmonary neuroendocrine tumors reveals prognostic and therapeutic markers (CSWOG-1901)[J]. Oncologist, 2022, 27(2): e116-e125. DOI: 10.1093/oncolo/oyab044. pmid: 35641209
[38]	Zhuo ML, Guan YF, Yang X, et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma[J]. Clin Cancer Res, 2020, 26(4): 892-901. DOI: 10.1158/1078-0432.CCR-19-0556. pmid: 31694833
[39]	Jelli B, Brandão M, Mekinda Z, et al. Systemic treatment for neuroendocrine non-small cell lung carcinoma: a cases series and a systematic review of the literature[J]. Lung Cancer, 2023, 181: 107232. DOI: 10.1016/j.lungcan.2023.107232.
[40]	Christopoulos P, Engel-Riedel W, Grohé C, et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase Ⅱ trial[J]. Ann Oncol, 2017, 28(8): 1898-1902. DOI: 10.1093/annonc/mdx268. pmid: 28535181
[41]	Hermans BCM, Derks JL, Thunnissen E, et al. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile[J]. Lung Cancer, 2019, 138: 102-108. DOI: 10.1016/j.lungcan.2019.10.010. pmid: 31678831
[42]	Blackhall F, Jao K, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study[J]. J Thorac Oncol, 2021, 16(9): 1547-1558. DOI: 10.1016/j.jtho.2021.02.009. pmid: 33607312
[43]	Morgensztern D, Johnson M, Rudin CM, et al. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study[J]. Lung Cancer, 2020, 145: 126-131. DOI: 10.1016/j.lungcan.2020.04.017. pmid: 32438272
[44]	Derks JL, Leblay N, Thunnissen E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome[J]. Clin Cancer Res, 2018, 24(1): 33-42. DOI: 10.1158/1078-0432.CCR-17-1921. pmid: 29066508

肺大细胞神经内分泌癌临床分子诊断和治疗研究进展

Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J]. 国际肿瘤学杂志, 2024, 51(7): 385-410.
[2]	Saber Amin, Chi Lin. 质子束放疗在中枢神经系统肿瘤患者中的应用趋势：美国国家癌症数据库分析（2004—2021年）[J]. 国际肿瘤学杂志, 2024, 51(7): 424-431.
[3]	梁新雨, 危志刚, 叶欣. 肺部磨玻璃结节的过度诊断与过度治疗现状及对策[J]. 国际肿瘤学杂志, 2024, 51(7): 432-440.
[4]	赵彪, 蒲琴, 袁美芳, 马立双, 李瀚, 杨毅, 孙朝细. 基于内缘切线野的调强放疗与容积弧形调强放疗在左侧乳腺癌保乳术后放疗中的剂量学研究[J]. 国际肿瘤学杂志, 2024, 51(7): 441-447.
[5]	刘昊, 靳二梅, 丁红娟, 金磊. 非小细胞肺癌患者血清HMGB2和HMGB3水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(7): 448-452.
[6]	余宏鑫, 白燕, 巩媛, 王健庄, 范志刚. 接受预防性脑部放疗局限期SCLC患者缓解后脑转移发生危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(7): 453-457.
[7]	刘晶, 张俊. 放射性碘难治性分化型甲状腺癌再分化治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 464-467.
[8]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[9]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[10]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[11]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.